China Universal Asset Management Co. Ltd. Grows Stock Holdings in BeiGene, Ltd. (NASDAQ:BGNE)

China Universal Asset Management Co. Ltd. grew its stake in shares of BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 69.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,510 shares of the company's stock after purchasing an additional 3,486 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in BeiGene were worth $1,911,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in BGNE. Blue Trust Inc. grew its holdings in BeiGene by 156.3% in the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company's stock worth $28,000 after acquiring an additional 75 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of BeiGene in the third quarter worth about $36,000. Headlands Technologies LLC purchased a new position in BeiGene during the 1st quarter valued at about $50,000. SG Americas Securities LLC bought a new position in BeiGene during the 3rd quarter valued at approximately $105,000. Finally, Acadian Asset Management LLC lifted its holdings in BeiGene by 204.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,265 shares of the company's stock worth $197,000 after buying an additional 849 shares during the period. Institutional investors own 48.55% of the company's stock.

Insider Transactions at BeiGene

In related news, CEO John Oyler sold 6,175 shares of the stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total transaction of $1,433,958.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other BeiGene news, insider Titus B. Ball sold 137 shares of the business's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total transaction of $26,021.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John Oyler sold 6,175 shares of the firm's stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total value of $1,433,958.50. The disclosure for this sale can be found here. Insiders sold 23,070 shares of company stock worth $4,901,050 over the last quarter. 7.43% of the stock is currently owned by insiders.

Analysts Set New Price Targets

BGNE has been the subject of a number of recent analyst reports. Bank of America decreased their target price on BeiGene from $180.00 to $152.50 and set a "neutral" rating for the company in a report on Tuesday, July 9th. Citigroup raised their target price on shares of BeiGene from $269.00 to $288.00 and gave the stock a "buy" rating in a research report on Thursday, August 8th. JPMorgan Chase & Co. increased their price target on shares of BeiGene from $200.00 to $235.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 22nd. Finally, JMP Securities initiated coverage on BeiGene in a research report on Wednesday, September 18th. They set a "market outperform" rating and a $288.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, BeiGene currently has an average rating of "Moderate Buy" and a consensus target price of $246.21.

BeiGene Stock Down 0.3 %

Shares of BGNE traded down $0.69 during mid-day trading on Tuesday, reaching $216.53. The company had a trading volume of 229,340 shares, compared to its average volume of 260,248. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98. The company has a market capitalization of $20.98 billion, a price-to-earnings ratio of -28.60 and a beta of 0.62. The firm has a 50-day moving average price of $210.64 and a 200 day moving average price of $176.45. BeiGene, Ltd. has a 52 week low of $126.97 and a 52 week high of $248.16.

BeiGene (NASDAQ:BGNE - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, beating the consensus estimate of ($2.27) by $1.12. The firm had revenue of $929.20 million during the quarter, compared to the consensus estimate of $810.34 million. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. The company's revenue was up 56.1% on a year-over-year basis. During the same period last year, the company earned ($3.64) earnings per share. On average, sell-side analysts forecast that BeiGene, Ltd. will post -5.07 EPS for the current year.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.